The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin

The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin

The 2 histone deacetylase inhibitors (HDACIs) approved for the treatment of cutaneous T-cell lymphoma (CTCL) including mycosis fungoides/sezary syndrome (MF/SS), suberoylanilide hydroxamic acid (SAHA) and romidepsin, are associated with low rates of overall response and high rates of adverse effects...

Full description

Bibliographic Details
Main Authors: Moyal, Lilach, Feldbaum, Nataly, Goldfeiz, Neta, Rephaeli, Ada, Nudelman, Abraham, Weitman, Michal, Tarasenko, Nataly, Gorovitz, Batia, Maron, Leah, Yehezkel, Shiran, Amitay-Laish, Iris, Lubin, Ido, Hodak, Emmilia
Format: Online
Language:English
Published: Public Library of Science 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709199/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709199/

Similar Items